Biotech IV Monitor

BMRN — BioMarin Pharmaceutical Inc.

$13.4B market cap · 8 upcoming readouts tracked

Clinical trial readout dates for BioMarin Pharmaceutical Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.

Next readoutApril 2027in ~5 months
Upcoming readouts82 Phase 3
Market cap$13.4B
Cash & investments$736M~6 quarters at last loss rate
Recent 8-K filings1latest 2026-11-02

Upcoming readouts

Phase 1/2 BMN 351
Duchenne Muscular Dystrophy · NCT06280209
April 2027
Ongoing
Phase 1/2 BMN 307
Phenylketonuria (PKU) · NCT04480567
December 2027
Ongoing
Phase 2 BMN 111
Achondroplasia · NCT02724228
December 2027
Ongoing
Phase 2 vosoritide
Achondroplasia · NCT04554940
December 2027
Ongoing
Phase 2 Vosoritide
Hypochondroplasia · NCT07126262
June 2028
Recruiting
Phase 1/2 Dose 1 of BMN 331
Hereditary Angioedema; HAE · NCT05121376
November 2028
Ongoing
Phase 2/3 BMN 333
Achondroplasia · NCT07441876
June 2029
Recruiting
Phase 3 BMN 111
Achondroplasia · NCT03424018
June 2031
Ongoing

Cash position

BioMarin Pharmaceutical Inc. reported $736M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $123M; at that rate the cash would last about 6 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-02

Companies working on similar indications

Discussion

No messages yet. If you follow BMRN, you can start the conversation.
Track BMRN in real time
See live implied volatility for BMRN and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on BMRN
Contact — questions or corrections about BMRN: dukeupt@gmail.com